• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Study Provides ‘Proof of Concept’ that Genetic Findings Can Lead to Drug Development


Surprising findings from the largest study to date investigating the genetics of osteoporosis and fracture risk.



A new study that sheds light on genes and bone fracture risk may help identify some targets for drug development.

Osteoporosis-related fractures were responsible for an estimated $19 billion in healthcare costs in 2005, with that figure expected to increase to $25 billion by 2025.

The genetic factors related to fracture in this largest genetic study of fracture to date, show that the genes discovered as being related to fracture are the same ones that have been found previously to be related to bone density-highlighting the importance of bone density to fracture risk.

For the study, published in the British Medical Journal, Douglas P. Kiel, MD, MPH, Professor of Medicine, Harvard Medical School, Director of Musculoskeletal Research at the Institute for Aging Research, Hebrew SeniorLife, and a team of researchers from the U.S., Europe, Canada, Asia, and Australia, performed a genome-wide association study with many sources of data from around the world. The researchers then curated previously reported genome-wide association studies of the “risk factors for fracture” (e.g., bone density, grip strength, vitamin D levels, etc.) and took the genetic factors for those studies to see if they predicted fracture and they did not in many instances.

Using mendelian randomization, an approach that takes advantage of the random assortment of genetic alleles at birth from the father and mother, the researchers were not able to confirm that many of the purported “risk factors” for fracture are likely causal.

The study provides evidence against a causal effect of several proposed clinical risk factors for fractures, including diabetes, rheumatoid arthritis, vitamin D, as well as others. These findings strongly suggest that treatments aimed at increasing bone strength are more likely to be successful in preventing fractures than widespread supplementation of calcium and vitamin D or targeting other risk factors that were not found to mediate the disease, according to the study authors.

“Only bone density was strongly related to fracture using this approach,” Kiel says. “Since there is a huge treatment gap of older adults with osteoporosis, whereby many people are not being prescribed therapy to prevent fractures, and since some of the available drugs have side effects, there is a need for new treatments to be developed. Second, our mendelian randomization results add further support to the growing recognition that in the general population, routine supplementation of vitamin D to prevent fractures is not likely to be successful.”

One of the strongest signals was near the cluster of genes that are called SOST, DUSP3, MEOX. One of the genes in this cluster is sclerostin, a protein that in humans is encoded by the SOST gene.

“This gene makes a protein, sclerostin, that inhibits the building of bones. There is currently a drug under review by the FDA for approval to treat osteoporosis,” Kiel says.  “The drug called romosozumab blocks the sclerostin to enable bone to be built up. This is a ‘proof of concept’ that genetic findings can lead to new drug development.”

Another gene, RSPO3, lies in the same path as SOST, as does the gene WNT16 on chromosome 7, again showing that genetic studies often identify the key “druggable” pathways related to diseases, according to Kiel.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.